Literature DB >> 26125130

The hepatic circadian clock regulates the choline kinase α gene through the BMAL1-REV-ERBα axis.

Aline Gréchez-Cassiau1, Céline Feillet, Sophie Guérin, Franck Delaunay.   

Abstract

The circadian timing system adapts most of the mammalian physiology and behaviour to the 24 h light/dark cycle. This temporal coordination relies on endogenous circadian clocks present in virtually all tissues and organs and implicated in the regulation of key cellular processes including metabolism, transport and secretion. Environmental or genetic disruption of the circadian coordination causes metabolic imbalance leading for instance to fatty liver, dyslipidaemia and obesity, thereby contributing to the development of a metabolic syndrome state. In the liver, a key metabolic organ, the rhythmic regulation of lipid biosynthesis is known, yet the molecular mechanisms through which the circadian clock controls lipogenesis, in particular, that of phospholipids, is poorly characterised. In this study, we show that the wild-type mice display a rhythmic accumulation of hepatic phosphatidylcholine with a peak at ZT 22-0 while clock-deficient Bmal1(-/-) mice show elevated phosphatidylcholine levels in the liver associated with an atherogenic lipoprotein profile. Profiling of the mRNA expression of enzymes from the Kennedy and phosphatidylethanolamine N-methyltransferase pathways which control the production of hepatic phosphatidylcholine revealed a robust circadian pattern for Chkα while other mRNA showed low amplitude (Chkβ and Pemt) or no rhythm (Cctα and Chpt1). Chkα mRNA expression was increased and no longer rhythmic in the liver from clock-deficient Bmal1(-/-) mice. This change resulted in the upregulation of the CHKα protein in these animals. We further show that the robust circadian expression of Chkα is restricted to the liver and adrenal glands. Analysis of the Chkα gene promoter revealed the presence of a conserved response element for the core clock transcription factors REV-ERB and ROR. Consistent with the antiphasic phase relationship between Chkα and Rev-erbα expression, in cotransfection experiments using HepG2 cells we show that RORα4-dependent transactivation of this element is repressed by REV-ERBα· Correspondingly, Rev-erbα(-/-)mice displayed higher Chkα mRNA levels in liver at ZT 12. Collectively, these data establish that hepatic phosphatidylcholine is regulated by the circadian clock through a Bmal1-Rev-erbα-Chkα axis and suggest that an intact circadian timing system is important for the temporal coordination of phospholipid metabolism.

Entities:  

Keywords:  Choline kinase α; Circadian clock; liver; phosphatidylcholine metabolism

Mesh:

Substances:

Year:  2015        PMID: 26125130     DOI: 10.3109/07420528.2015.1046601

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  4 in total

Review 1.  Circadian Regulation and Clock-Controlled Mechanisms of Glycerophospholipid Metabolism from Neuronal Cells and Tissues to Fibroblasts.

Authors:  Mario E Guido; Natalia M Monjes; Paula M Wagner; Gabriela A Salvador
Journal:  Mol Neurobiol       Date:  2021-10-26       Impact factor: 5.590

2.  Genetic Variation in Choline-Metabolizing Enzymes Alters Choline Metabolism in Young Women Consuming Choline Intakes Meeting Current Recommendations.

Authors:  Ariel B Ganz; Vanessa V Cohen; Camille C Swersky; Julie Stover; Gerardo A Vitiello; Jessica Lovesky; Jasmine C Chuang; Kelsey Shields; Vladislav G Fomin; Yusnier S Lopez; Sanjay Mohan; Anita Ganti; Bradley Carrier; Olga V Malysheva; Marie A Caudill
Journal:  Int J Mol Sci       Date:  2017-01-26       Impact factor: 5.923

3.  Regulation of protein-coding gene and long noncoding RNA pairs in liver of conventional and germ-free mice following oral PBDE exposure.

Authors:  Cindy Yanfei Li; Julia Yue Cui
Journal:  PLoS One       Date:  2018-08-01       Impact factor: 3.240

Review 4.  Choline Kinase: An Unexpected Journey for a Precision Medicine Strategy in Human Diseases.

Authors:  Juan Carlos Lacal; Tahl Zimmerman; Joaquín M Campos
Journal:  Pharmaceutics       Date:  2021-05-25       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.